4
Changes in Ownership
Contineum Therapeutics, Inc. Filed Acc 0001437749-26-002575
CMO & Head of Development sold 3,611 shares at an average $14.18 ($51,188)
- CMO & Head of Development acquired 3,611 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Watkins Tim CMO & Head of Development | 2026-01-28 | Option exercise 10b5-1 | +3,611 | $4.50 | $16,250 | 3,611 | D |
| Watkins Tim CMO & Head of Development | 2026-01-28 | Sale 10b5-1 | −2,800 | $14.09 | $39,441 | 811 | D |
| Watkins Tim CMO & Head of Development | 2026-01-28 | Sale 10b5-1 | −811 | $14.48 | $11,747 | 0 | D |
| Derivatives | |||||||
| Watkins Tim CMO & Head of Development | 2026-01-28 | Option exercise · Stock Option (right to buy) 10b5-1 | −3,611 | 252,778 | D | ||
| Watkins Tim CMO & Head of Development | 2026-01-30 | Grant or award · Stock Option (right to buy) 10b5-1 | +160,000 | 160,000 | D | ||
| Open-market sales · 3,611 sh · avg $14.18 · $51,188 | |||||||
Loading xslF345X05/rdgdoc.xml…